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ABSTRACT
Effective therapies are urgently needed for COVID-19. Here we describe the identification of a new stable 
human immunoglobulin G1 heavy-chain variable (VH) domain scaffold that was used for the construction 
of a large library, lCAT6, of engineered human VHs. This library was panned against the receptor-binding 
domain (RBD) of the SARS-CoV-2 spike (S) glycoprotein. Two VH domains (VH ab6 and VH m397) were 
selected and fused to Fc for increased half-life in circulation. The VH-Fc ab6 and m397 specifically 
neutralized SARS-CoV-2 with high potencies (50% neutralization at 0.35 µg/ml and 1.5 µg/ml, respectively) 
as measured by two independent replication-competent virus neutralization assays. Ab6 and m397 
competed with ACE2 for binding to RBD, suggesting a competitive mechanism of virus neutralization. 
These VH domains may have potential applications for prophylaxis and therapy of COVID-19 alone or in 
combination, as well as for diagnosis and as tools for research.
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As of early 2020, the severe acute respiratory syndrome cor-
onavirus 2 (SARS-CoV-2)1 has spread worldwide and became 
a global pandemic.2,3 Recent statistics showed that more than 
3 million people were confirmed positive of virus infection 
globally, and the number is growing. Safe and effective preven-
tions and therapies are therefore urgently needed. Before an 
effective vaccine is available, passive antibody therapy will play 
an important role in medical care. Human monoclonal anti-
bodies (mAbs), which are typically target-specific and nontoxic 
to humans, are promising therapeutics4,5 as COVID-19 inter-
ventions based on the experience from human mAbs against 
other emerging viruses, including SARS-CoV, MERS-CoV, 
and henipaviruses.6-8 More than 80 antibody therapeutics 
have been granted marketing approval and more than 570 
antibody-derived candidates are being investigated in clinical 
trials.9,10 Here, we describe the potent neutralization of SARS- 
CoV-2 by human VH domains isolated from a large phage- 
displayed library with a new stable scaffold.
Results
Phage display is well established among in vitro mAb selection 
technologies,11-13 and more than 12 antibodies isolated by 
phage display of different format libraries have been approved 
for therapy.14 Human VH domains are relatively small and 
could interact with amino acid residues in the target which are 
not accessible by larger antibody fragments. Importantly, their 
small size would allow better penetration in normal and dis-
eased tissue. Previously, we demonstrated the construction of 
a human antibody variable heavy-chain (VH) domain library 
based on a VH scaffold from IGHV3-23, and isolated neutra-
lizers against HIV-1 from this library.15 In recent studies, more 
VH scaffolds, including IGHV3-7, IGHV4-34, IGVH1-69, 
IGVH3-15, and IGVH5-51, were chosen for library construc-
tion based on their frequency in the memory compartment of 
the immune repertoires.16,17
A major concern for generation of VH-based therapeutics is 
their stability. To identify a relative stable scaffold for VH 
libraries but without introducing mutations leading to poten-
tial immunogenicity we screened natively occurring stable VH 
scaffolds using a heat denaturation and refolding strategy.18 
We constructed a small VH phage-displayed library (size 
~1 × 107) from 3 healthy human donors’ peripheral blood 
mononuclear cells (PBMCs) and heated it at 80°C for 20 min-
utes. Chilled phages were spun down and supernatant was 
collected for bacterial TG1 infection. After three rounds of 
heating, refolding, and amplification, we evaluated a panel of 
stable VH scaffolds (Figure 1(a)). One VH scaffold, mCAT1, 
which is of IGHV3-30, was selected. This scaffold was mono-
meric as determined by size exclusion chromatography (SEC) 
(Figure 1(b)) and dynamic light scattering (DLS) (Figure 1(c)). 
It was stable at 37°C and showed less than 1% aggregation after 
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incubation for 14 days (Figure 1(c)). Other highly enriched 
scaffolds, IGHV3-7, IGHV4-34, are shown in Fig. S1.
A VH domain library, lCAT6, was constructed by grafting 
naturally occurring CDR2 s and CDR3 s from human PBMCs 
to mCAT1 as well as to IGHV3-7-, IGHV4-34-, and IGVH3- 
23-based scaffolds following the strategy described 
previously.15 The IGHV3-7-, IGHV4-34-, and IGVH3-23- 
based scaffolds were added to increase diversity although the 
mCAT1 scaffold was still dominant representing 40% of the 
clones. The library construction is shown in Fig.S2. No repeat-
ing sequences were found in 100 clones indicating good diver-
sity. In addition, only 21% of the clones were nonproductive 
(10% of clones had stop codons, and 11% of clones were out of 
frame). The size of the library was estimated to be 7.9 × 1010 
after subtracting the nonproductive clones based on the titra-
tion of transformants. The library functionality was tested by 
panning it against a human protein antigen that is unrelated to 
the RBD of the SARS-CoV-2 spike protein; two high-affinity 
binders, VH X and VH Y, were selected which did not aggre-
gate after incubation at 37°C for 14 days as measured by DLS 
(Figure 1(d)).
We used ICAT6 for the selection of high-affinity VH 
domains by panning it against recombinant SARS-CoV-2 
RBD developed in our laboratory. We identified a panel of 
binders, two of which, ab6 and m397, were further character-
ized for affinity, competition with the SARS-CoV-2 receptor 
ACE2, and neutralization.
Both VH ab6 and m397 bound cell surface-associated 
native S glycoprotein, confirming that their epitopes are 
accessible and not changed on the native S protein (Figure 2 
(a)). The equilibrium dissociation constant, Kd, of these VH 
binders (ab6 and m397) to recombinant RBD as measured by 
BLItz was 4.6 nM and 29.2 nM, respectively (Figure 2(b)). 
Both ab6 and m397 competed with ACE2 for binding to the 
RBD (Figure 3(a)), indicating that the virus could be neutra-
lized by preventing its binding to the receptor. To extend their 
in vivo half-lives and potentially their neutralizing activity, we 
converted ab6 and m397 to the Fc fusion proteins VH-Fc ab6 
and VH-Fc m397, respectively. Both VH-Fc ab6 and VH-Fc 
m397 bound cell-surface-associated native S glycoprotein 
(Figure 2(c)). The Kd of the VH-Fc ab6 and VH-Fc m397 to 
recombinant RBD as measured by BLItz was 11 nM and 
9.6 nM, respectively (Figure 2(d)). Interestingly and rather 
unusual, the VH-Fc ab6 exhibited higher Kd (11 nM) to RBD 
compared to VH ab6 (4.6 nM) mostly due to its significantly 
decreased association rate constant ka – about 10-fold – 
smaller than that for m397 (about fourfold decrease). Part of 
this decrease is due to the larger size of the VH-Fc compared 
to VH resulting from the smaller ratio of the paratope to the 
total area of the molecule and decreasing the number of 
effective encounters by Brownian motion as is also for 
m397. However, significant portion could be due to other 
factors which remain to be elucidated. In addition, the gain 
in the dissociation rate constant (about four times, due to 
avidity because of increased local concentration) for ab6 is 
smaller than that for m397 which is about 10 times. The 
unusually large decrease in the association rate constant com-
bined with the relatively small decrease in the dissociation 
rate constant resulted in the relatively rare situation when 
avidity of binding is weaker than affinity, one should also 
take into account that there are two VHs in Fc fusion protein 
and that avidity depends on the surface concentration of the 
Figure 1. Identification and characterization of the mCAT1 scaffold. (a) Isolated human VH genes from multiple heating selection steps. Highly enriched VH frameworks 
are highlighted in yellow. (b) Size exclusion chromatography profiles for VH (mCAT1, IGVH3-30) scaffold. Known monomeric VH (m33) and dimeric VH (m85) were used 
for control. (c) Dynamic light scattering analysis for evaluation of the aggregation propensity of the VH (mCAT1) scaffold. The mCAT1 VH was incubated at 37°C for 
indicated days. Around 4 nm size corresponded to that of a 12.5 kDa VH. (d) Dynamic light scattering analysis of VH binders X and Y. The antibodies were incubated at 
37°C for indicated days. Different color curves mean repeats of data reading.
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Figure 2. Binding characterization of VH ab6 and m397 with or without human IgG1 Fc. (a) Flow cytometry analysis for binding of VH ab6 and m397 to S-glycoprotein 
expressed on the surface of HEK293 T cell (293 T-S). (b) Representative sensorgrams for VH ab6 and m397. Equilibrium dissociation constants (Kd) = 4.6 nM (ka = 4.4E4 1/ 
Ms, kd = 2.0E-4 1/s) and 29.2 nM (ka = 1.3E5 1/Ms, kd = 3.9E-3 1/s), respectively. (c) Flow cytometry analysis for binding of VH-Fc ab6 and m397 to S-glycoprotein 
expressed on the surface of HEK293 T cell. (d) Representative sensorgrams for VH-Fc ab6 and m397. Equilibrium dissociation constants (Kd) = 11 nM (ka = 4.6E3 1/Ms, kd 
= 5.3E-5 1/s), and 9.6 nM (ka = 3.4E4 1/Ms, kd = 3.3E-4 1/s), respectively.
Figure 3. Competition with ACE2-Fc and SARS-CoV-2 neutralization activity of ab6 and m397. (a) Competitive ELISA of ACE-Fc binding to plate-immobilized 
recombinant SARS-CoV-2 RBD in the presence of increasing concentrations of anti-RBD VH ab6 and m397, or VH m398 as a negative control (m398 binds to RBD 
but does not compete with ACE2). After the competition, bound biotinylated ACE-Fc was detected by SA-HRP. (b) Microneutralization assay. VH-Fc ab6 exhibited 
significant neutralization activity against SARS-CoV-2 = 100% at 0.4 µg/ml (5.3 nM). Neutralization activity was measured by observation of virus-induced formation of 
cytopathic effect of Vero E6 cells. The m336 (MERS-CoV neutralizing human IgG1) was used as negative control. (c) Luciferase reporter gene assay for measurement of 
SARS-CoV-2 neutralizing capacity. The proteins used were Fc-fusions (VH-Fc ab6 and VH-Fc m397). The VH-Fc ab6 and m397 exhibited neutralizing activity against SARS- 
CoV-2 with high potencies – IC50 = 0.35 µg/ml (4.6 nM) and 1.5 µg/ml (20 nM), respectively. IgG1 m336 was used as negative control.
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target molecules. We plan to study the mechanism of this 
unusual finding in detail including dose-dependent binding to 
native S protein expressed in virions and on the cell surface. 
Consistent with weaker binding compared to VH ab6, VH-Fc 
ab6 showed decreased competition with ACE2 for binding to 
RBD compared to VH ab6, while VH-Fc m397 exhibited 
stronger competition to ACE2 compared to VH m397 due 
to its enhanced binding avidity to RBD (Figure 3(a)).
VH-Fc ab6 was further characterized by both a standard 
microneutralization-based assay and a luciferase reporter gene 
assay to determine its neutralizing activity against live SARS- 
CoV-2 virus, whereas VH-Fcm397 was evaluated only by the 
luciferase reporter gene assay. VH-Fc ab6 and VH-Fc m397 
exhibited potent activity, neutralizing 50% of the virus at con-
centrations of 0.35 µg/ml (≈4.6 nM) and 1.5 µg/ml (≈20 nM), 
respectively, as measured by the luciferase reporter gene assay; 
VH-Fc ab6 neutralized 100% live virus at 0.4 µg/ml and 0% at 
0.1 µg/ml as measured by the microneutralization-based assay 
(Figure 3(b,c)) which is consistent with the result from the 
reporter gene assay. In agreement with the specificity of bind-
ing to the SARS-CoV-2 RBD and not to the SARS-CoV RBD, 
neither VH-Fc ab6 nor VH-Fc m397 neutralized live SARS- 
CoV. One control, our IgG1 m336,19 which is a potent neu-
tralizer of MERS-CoV (neutralized 50% live MERS-CoV at 
0.07 μg/ml), did not exhibit any neutralizing activity against 
SARS-CoV-2. Interestingly, VH-Fc ab6, which showed weaker 
competition to ACE2 than VH-Fc m397, more potently neu-
tralized live SARS-CoV-2 than VH-Fc m397, indicating an 
additional ACE competition independent neutralization 
mechanism for VH-Fc ab6 which could be through affecting 
the S protein conformation. This interesting neutralization 
phenomenon also suggests that ab6 targets a unique epitope 
on RBD perhaps which could be very different from that of 
m397. Future experiments are being planned to further char-
acterize the neutralizing activity of these mAbs in vitro and 
in vivo alone or in combination with inhibitors as well as to 
extensively characterize their biophysical properties including 
their structures in complex with the S protein.
Discussion
Human antibody VH domains are promising therapeutic can-
didates. In this study, we constructed a large nonimmune 
human VH domain antibody phage-displayed library, ICAT6, 
based on relatively stable VH scaffolds, from which two potent 
SARS-CoV-2-binding antibodies ab6 and m397 were selected 
and characterized. Recently, two articles described the isolation 
of antibody domains against the SARS-CoV-2.20,21 Those 
domains were of relatively modest activity and tested only by 
using pseudovirus assays. The VH-Fc ab6 and m397 exhibited 
very high inhibitory activity against live virus. VH-Fc ab6 was 
tested by using two different assays in two different laboratories 
with essentially the same results. The high affinity/avidity of 
these mAbs, and their high efficacy in neutralizing live virus, 
suggest their potential application for prophylaxis and therapy 
of SARS-CoV-2 infections alone or in combination, as well as 
for research studies to explore mechanisms of antibody–anti-
gen interactions and for diagnosis.
Materials and methods
Library construction and panning
A large phage-displayed human VH library (≈8.9 × 1010 clones) 
was constructed by grafting of naturally occurring heavy-chain 
CDR2 s and CDR3 s from cDNA of a 10 donor-PBMC pool to 
VH framework scaffolds (Figure 1) as previously described.15 
After library construction, we sequenced 100 clones and did not 
observe any repetitive sequences, indicating a good diversity of 
the library. The antibody phage-displayed libraries were preab-
sorbed on streptavidin-M280-Dynabeads in phosphate-buffered 
saline (PBS) for 1 h at room temperature (RT) and incubated 
with 50 nM biotinylated SARS-CoV-2 RBD (residues 330–532) 
for 2 h at RT with gentle agitation. Phage particles binding to 
biotinylated antigen were separated from the phage library using 
streptavidin-M280-Dynabeads and a magnetic separator 
(Dynal). After washing 20 times with 1 ml of PBS containing 
0.1% Tween-20 and another 20 times with 1 ml of PBS, bound 
phage particles were eluted from the beads using 100 mM 
triethanolamine followed by neutralization with 1 M, pH7.5 
Tris-HCl. For the second round of panning, 10 nM (2 nM for 
the third round) of biotinylated antigen was used as antigen. 
After the third round of panning against 2 nM biotinylated 
antigen, 96 individual clones were screened for binding to RBD- 
Fc fusion protein by phage ELISA. Panels of VHs were selected 
and sequenced, and 16 unique sequences were identified.
Expression, purification of SARS-CoV-2 RBD-his, 
SARS-CoV-2 RBD-Fc, ACE2-FC, and VH binders, and 
conversion of the VH binders to Fc fusion proteins
The gene of SARS-CoV-2 surface glycoprotein was synthesized 
by IDT (Coralville, Iowa), and the ACE2 gene was ordered 
from OriGene (Rockville, MD). The sequences were obtained 
from GenBank® (https://www.ncbi.nlm.nih.gov/genbank/sars- 
cov-2-seqs/). The RBD domain (residues 330–532), S1 domain 
(residues 14–675), and ACE2 (residues 18–740) genes were 
cloned into an expression plasmid. This plasmid contains 
a CMV promotor and woodchuck posttranscriptional regula-
tory elements, with human IgG1 Fc or His tag, respectively. 
Proteins were expressed with Expi293 expression system 
(Thermo Fisher Scientific) and purified with protein A resin 
(GenScript). Protein purity was estimated as >95% by SDS- 
PAGE and protein concentration was measured spectrophoto-
metrically (NanoVue, GE Healthcare). For conversion to Fc- 
fusion, the VH gene was re-amplified and re-cloned into 
pSectaq vector (containing human Fc). Protein purity was 
estimated as >95% by SDS-PAGE and protein concentration 
was measured spectrophotometrically (NanoVue, GE 
Healthcare). VH ab6, VH m397, and VH m398 (not published) 
were in pComb3x vector. Purification of VH binders was 
performed in Escherichia coli HB2151 bacterial culture at 30° 
C for 16 h with stimulation by 1 mM IPTG. Cells were har-
vested and lysed by Polymyxin B (Sigma–Aldrich) at 37°C for 
0.5 h. Supernatant was loaded over Ni-NTA (GE Healthcare). 
Purity was estimated to be over 95% by SDS-polyacrylamide 
gel electrophoresis, and protein concentration was measured 
spectrophotometrically (NanoVue, GE Healthcare).
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ELISA
Antigen protein was coated on a 96-well plate (Costar) at 50 
ng/well in PBS overnight at 4°C. For the soluble VH binding 
assay, horseradish peroxidase (HRP)-conjugated mouse anti- 
FLAG tag antibody (A8592, Sigma–Aldrich) was used to detect 
VH binding. For the competition ELISA, 2 nM of biotinylated 
human ACE2-Fc was incubated with serially diluted VH or Fc- 
fused VH, and the mixtures were added to antigen (RBD)- 
coated wells. After washing, bound biotinylated human ACE2- 
Fc was detected by HRP-conjugated streptavidin (P9170, 
Sigma–Aldrich).
BLItz
Both affinities (ab6 and m397) and avidities (VH-Fc ab6 and 
VH-Fc m397) of anti-RBD VHs were analyzed by biolayer 
interferometry BLItz (ForteBio, Menlo Park, CA). To measure 
affinity, protein A biosensors (ForteBio:18–5010) were coated 
with RBD-Fc for 2 min and incubated in Dulbecco’s PBS 
(DPBS) (pH = 7.4) to establish baselines. Different doses of 
VHs were used for association. To measure avidity, RBD-Fc 
was biotinylated with EZ-link sulfo-NHS-LC-biotin (Thermo 
Fisher Scientific, Waltham, MA) (RBD-Fc-Bio), and streptavi-
din biosensors (ForteBio:18–5019) were coated with RBD-Fc- 
Bio for 2 min and incubated in DPBS (pH = 7.4) to establish 
baselines. Biosensor only with antibodies and antigen-coated 
biosensor with PBS were served as reference controls. Different 
doses of VHs-Fc were recruited for association. The association 
was monitored for 2 min and dissociation was monitored in 
DPBS for 4 min.
Flow cytometry
Full-length S protein of SARS-CoV-2 with replacement of 
native signal peptide by the CD5 signal peptide was codon- 
optimized and synthesized (IDT). S gene-containing plasmid 
was used for transient transfection of 293 T cells cultured in 
Dulbecco’s Modified Eagle’s Medium with 10% fetal bovine 
serum. The transient expression level was tested by fluores-
cence-activated cell sorting (FACS) using the recombinant 
hACE2-Fc and IgG1 CR3022. And 1 μM antibodies were 
added to 1 × 106 cells for staining. Phycoerythrin (PE)- 
conjugated anti-human Fc antibody (P9170, Sigma–Aldrich) 
and viability dye were used to detect antibody-bound cells. For 
detecting VH antibodies, DYKDDDDK Antibody (130–101- 
576, Miltenyi Biotec) and viability dye were used. FACS ana-
lysis was performed on a BD LSR II (San Jose, CA). Single cells 
were gated first, followed by gating of live cells. PE-A+ popula-
tion was gated based on live cells. FACS binding analysis was 
performed using FlowJo_V10_CL.
Micro-neutralization assay
The standard live virus-based microneutralization assay was 
used for measurement.22 Serially diluted test antibodies were 
prepared in 96-well microtiter plates with a final volume of 
60 μl per well before adding 120 infectious units of SARS-CoV 
or SARS-CoV-2 in 60 μl to individual wells. After 2 h culturing 
at room temperature, 100 μl of the antibody-virus mixtures 
were transferred into designated wells of confluent Vero E6 
cells grown in 96-well microtiter plates. Vero E6 cells with or 
without virus infection served as positive and negative con-
trols, and Vero E6 cells treated with the MERS-CoV RBD- 
specific neutralizing m336 mAb were included as an additional 
control. Virus-induced formation of cytopathic effect was 
detected by microscopy after four days of incubation at 37°C. 
The work was performed in the Department of Microbiology & 
Immunology, Centers for Biodefense and Emerging Diseases, 
Galveston National Laboratory, 301 University Blvd, 
Galveston, Texas 77550, USA.
Reporter gene neutralization assay
Full-length viruses expressing luciferase were designed and 
recovered.23 Viruses were titered in Vero E6 USAMRID cells 
before experiments. Vero E6 USAMRID cells were plated at 
20,000 cells per well in clear-bottom black-walled 96-well plates 
(Corning 3904) one day before experiments. Antibody samples 
were fourfold serially diluted from 100 μg/ml. SARS-CoV- 
UrbaninLuc and SARS-CoV-2-SeattlenLuc viruses were mixed 
with serially diluted antibodies according to the University of 
North Carolina safety rules and were incubated at 37°C with 5% 
CO2 for one hour. After incubation, growth media was removed 
from cells and virus-antibody dilution complexes were added to 
the cells. Virus-only controls and cell-only controls were 
included in each assay. After infection, cells were incubated at 
37°C with 5% CO2 for 48 hours and then were lysed and 
luciferase activity was measured via Nano-Glo Luciferase Assay 
System (Promega). Experiments were performed in duplicate 
and IC50 was analyzed by Graphpad Prism 7 under “sigmoidal 
dose-response (variable slope)” equation.
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